However, this is the first report showing that tofogliflozin provided additional reductions in HbA1c with weight loss and reduction in blood pressure without an increase in insulin and glucagon in patients with type 2 diabetes mellitus who had been treated with GLP‐1 receptor agonist monotherapy but were inadequately controlled. This evidence concerns the gene GCG and type 2 diabetes mellitus.